20 Co-stimulation blockade of CD40/CD40L in SLE and beyond
Learning Objectives. Discuss the different mechanisms of action of belimumab and anifrolumab and their roles in modulating immune pathways in SLE .Explain the clinical indications, efficacy data, and trial outcomes (BLISS and TULIP studies) of BEL and ANI in systemic lupus erythematosus .Apply clinical reasoning to choose between BEL and ANI based on patient phenotype, disease activity, and safety considerations
Authors
- Zahir Amoura (ORCID: https://orcid.org/0000-0003-0292-9043)
Institutions
- Sorbonne Université (FR)
- Laboratoire National de Référence (MA)
Publication Details
- Journal
- Abstracts
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/lupus-2025-la.20
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00